NEWS

KRAS-variant

New Research: How Inherited DNA -Based Mutations Impact Immunotherapy

The partners on the UCLA research team have made new discoveries about how genetic mutations can help doctors predict patient responses to cancer-fighting immunotherapy drugs. In the past, we’ve spoken a lot...

Read More

What You Need to Know About Estrogen and the KRAS-variant

Joanne Weidhaas is MiraKind’s founder and one of the scientists responsible for discovering the KRAS-variant, an inherited genetic mutation which predicts an increased risk of cancer. Following this breakthrough, Weidhaas and her...

Read More

Why you should get your KRAS-variant results

Dear study participants, I wanted to share an experience that I had today. I had a wonderful conversation with a woman who participated in the first MiraKind study.  While I always enjoy...

Read More

The truth about GWAS and the KRAS-variant

Although much of the world has accepted that GWAS studies, which use an outdated technology looking at large amounts of data, have failed to find any functional mutations, this approach has twice...

Read More

How does breast cancer treatment impact second breast cancer risk?

We are embarking on a study to explore how breast cancer management strategies (e.g., chemotherapy, surgery, hormones) that are used to treat breast cancer, impact breast cancer risk for women with the...

Read More

DONATE

SUPPORT OUR RESEARCH

PARTICIPATE

HELP ADVANCE OUR RESEARCH